teladoc glp-1 receptor agonist weight management diabetes treatments Health Partners with Eli Lilly to Offer Self-Pay Option for GLP-1 Medications for Weight Loss:

Diabetes 63 , 24742485 (2014)

Sample sizes ranged from 24 to 252 participants, with larger studies often exploring long-term preventive effects of GLP-1

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity

Mol Psychiatry 28 , 217229 (2023)

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation

LIMITATIONS, REASONS FOR CAUTION Study limitations include the absence of data regarding medication compliance post prescription redemption, potential misclassification due to parallel importation, and the inability to control for unmeasured confounding factors